Semaglutide-Related Poison Control Calls Increase After Weight Management Approval
Poison control calls involving semaglutide (Ozempic and Wegovy) soared after the drug was approved for weight management, with researchers linking the increase to accidental dosing mistakes rather than intentional misuse
Semaglutide-related poison control calls have increased significantly following the approval of the medication for weight management. The authors note that these incidents are largely attributed to accidental dosing mistakes, rather than intentional misuse. This highlights the importance of proper education and guidance on safe dosing practices for this medication. Simple measures such as gradual dose increases and clear instructions can help prevent many of these avoidable incidents. Furthermore, researchers emphasize the need for increased awareness among healthcare providers and patients about the potential risks associated with semaglutide use. By addressing these issues, it may be possible to reduce the number of poison control calls related to this medication. The findings of this study underscore the importance of responsible prescribing practices and patient education in minimizing adverse events.